Dechra Veterinary Products announces it has an exclusive marketing, sales and distribution agreement with Kindred Biosciences for the only FDA-approved drug for controlling pyrexia.

The agreement provides Dechra was the long-term distribution rights to Zimeta, an intravenous, non-steroidal anti-inflammatory injection that rapidly and effectively controls fever in horses during clinical studies.

“We are pleased to have partnered with Kindred Biosciences to add Zimeta to our equine product lines in the United States and Canada,” says Mike Eldreed, president of Dechra’s North American operations. “Dechra’s equine sales team is excited to launch Zimeta and provide veterinarians with a novel product to help control fevers in horses.”